Chiron at the Crossroads

Three years into a new CEO's regime, Chiron is trying to forge a unique compromise between research and commercial focus and the stability which comes from a diversified business. But Chiron is at a crossroads: its earnings growth, boosted significantly by a now complete cost-reduction program, doesn't look sustainable without major new products. And those Chiron does not appear to have. Moreover, its major shareholder, Novartis, has an option to buy the company and top management fears they will should the stock show significant signs of weakness, brought on, perhaps, by investments (and consequent earnings reductions) in potential high-growth areas. In effect, Chiron managers are afraid to invest significantly for fear of what Novartis will do should the stock price fall. Moreover, to some degree, Chiron is caught by its business diversity: it can't focus its spending on any one area, particularly biopharmaceuticals, without starving its other businesses--but without a significant increase in R&D spending, particularly in the drug unit, observers don't see how Chiron, which has been uniquely unsuccessful with its pipeline projects, can drive the long-term earnings growth it needs.

by Roger Longman

Last October 2000, Sean Lance, the chairman and CEO of Chiron Corp. , crossed paths with Daniel Vasella, chairman...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business Strategy

When VC Steps Back: Finding Alternative Biotech Funding

 
• By 

The biotech funding landscape is undergoing a fundamental shift. With traditional VC becoming increasingly cautious and selective, industry executives are exploring new avenues for capital. Conversely, this evolution may ultimately benefit the sector's long-term sustainability.

Podcast: “They Are Able To Keep Their Body”: Medipost On Its Stem Cell Therapy Vision

 

In Vivo spoke with Edward Ahn, CEO of Medipost, a Korean company that has developed stem cell therapies from cord blood, on how they are working across regulatory markets to provide a novel treatment for degenerative diseases.

Can Italy Shake Off Its Reputation And Become A Premier Hub For Biotech?

 
• By 

Leading industry experts have spoken to In Vivo about how investment, a change in mindset and a fresh approach to policy may allow Italy to kick-start its biotech ecosystem.

Rising Leaders 2025: Abbas Kazimi’s Vision For Nimbus Therapeutics

 
• By 

Rising Leader Abbas Kazimi's leadership at Nimbus Therapeutics combines immigrant resilience, patient-first partnerships, contrarian strategic bets and a deeply personal mission driving breakthrough drug discovery innovation.

More from In Vivo

When VC Steps Back: Finding Alternative Biotech Funding

 
• By 

The biotech funding landscape is undergoing a fundamental shift. With traditional VC becoming increasingly cautious and selective, industry executives are exploring new avenues for capital. Conversely, this evolution may ultimately benefit the sector's long-term sustainability.

Podcast: Inside MoonLake’s Fast-Track Vision And $500m Deal

 
• By 

MoonLake Immunotherapeutics is racing ahead in the biotech space with its innovative nanobody SLK and a transformative $500m non-dilutive financing deal. In this episode, its CEO and CFO discuss the company’s rapid clinical progress, financial strategy and ambitions to reshape inflammatory disease.

When Simple Is Best: A Pre-Term Birth Device To End The ‘Silent Emergency’

 
• By 

The Lioness non-surgical silicon ring implant is designed to put an end to pre-term births, sparing maternal anguish and saving health system costs. PregnanTech won the Biomed Israel 2025 medtech start-up award, and Limor Sandach told In Vivo how a non-digital technology beat off stiff competition.